Clinical trials: Cancer, Bladder
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer
Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
The standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which is rarely curative. Platinum-based neoadjuvant chemotherapy is associated with an improvement in Overall Survival (OS), but only a few…
- Trial name
- NEODURVARIB (NCT03534492)
- Testing
- Durvalumab, Olaparib
- Where
- 10 sites in Spain
- Volunteers
- 29 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Locally Advanced or Metastatic Urothelial Bladder Cancer
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial…
- Trial name
- NCT04004221
- Testing
- Tislelizumab
- Where
- 27 sites in China, South Korea
- Volunteers
- 113 people
- Sponsor
- BeiGene
Cancer Patients Receiving Stereotactic Body RTX
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
This prospective protocol will enroll patients with pathologically confirmed solid malignancies who receive stereotactic body radiation therapy (SBRT) for oligometastases, for consolidation after systemic therapy, prior to…
- Trial name
- NCT02170181
- Testing
- SBRT
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- University of Texas Southwestern Medical Center
Urinary Bladder Cancer
Patterns of Urinary Bladder Cancer in Darfur, Suda
Background: Bladder cancer (BC) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution.
- Trial name
- NCT06156787
- Where
- Sudan
- Volunteers
- 105 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease
Bladder Cancer
Validity of Parametric MRI Using VIRADS
Our aim in this prospective study is to evaluate the validity of the non-contrast biparametric MRI (bp-MRI), including T2-WI and DWI sequences, and the availability of an alternative to the mp-MRI, for the muscle invasiveness…
- Trial name
- metricMRI (NCT05783271)
- Testing
- Gadolinium
- Where
- Egypt
- Volunteers
- 58 people
- Sponsor
- Assiut University
Breast Cancer, Bladder Cancer
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
The primary objectives of this study are (1) to compare the incidence of breast cancer, by insulin use at cohort entry, among females with type 2 diabetes who are new users of dapagliflozin and females who are new users of…
- Trial name
- NCT02695121
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 2,133,575 people
- Sponsor
- AstraZeneca
Bladder Cancer, Urothelial Carcinoma
Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study
The purpose of this study is to explore the feasibility and efficacy of a 12-week, home-based exercise program in bladder cancer patients undergoing curative intent neoadjuvant chemotherapy and RC.
- Trial name
- NCT04223063
- Testing
- Exercise program
- Volunteers
- 20 people
- Sponsor
- Ross Mason
Gall Bladder Carcinoma
Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality
Incidental gallbladder carcinoma :Incidence and clinical significance in specimens from routine cholecystectomies in sohag locality
- Trial name
- NCT07885800
- Testing
- histopathology of gall bladder
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Bladder Cancer
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
- Trial name
- NCT00136175
- Testing
- Paclitaxel, Carboplatin, Gemcitabine
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Bladder Cancer, Disease Progression
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive…
- Conditions
- Bladder Cancer, Disease Progression, Recurrent Bladder Cancer
- Trial name
- NCT03174912
- Testing
- Intravesical BCG instillation
- Volunteers
- 400 people
- Sponsor
- Ankara Training and Research Hospital
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00310011
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Wake Forest University Health Sciences
Urinary Bladder Neoplasms
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC.
- Trial name
- NCT04109092
- Testing
- E7766
- Where
- 9 sites in United States
- Sponsor
- Eisai Inc.
Urothelial Cancer, Bladder Cancer
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
This study will evaluate the safety and efficacy of the combination of ABI-007, carboplatin and gemcitabine in the treatment of patients with advanced bladder cancer.
- Trial name
- NCT00995488
- Testing
- ABI-007 (Abraxane®)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Uterine Cancer, Cervical Cancer
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
The goal of this clinical research study is to use CT scans to find any changes in position of the vagina and pelvic lymph node areas during the course of IMRT radiation therapy.
- Conditions
- Uterine Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT00508703
- Testing
- Intensity Modulated Radiotherapy (IMRT), CT Scan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Oncology, Breast Cancer
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further…
- Conditions
- Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
- Trial name
- MOMENTUM (NCT04075305)
- Testing
- Radiation therapy
- Where
- 18 sites in United States, Australia and 7 more
- Volunteers
- 8,000 people
- Sponsor
- UMC Utrecht
Urothelial Carcinoma, Bladder Cancer
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).
- Trial name
- NCT01042795
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Bladder Carcinoma in Situ (CIS)
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or…
- Trial name
- NCT05024773
- Testing
- ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
- Where
- 47 sites in United States, France and 4 more
- Volunteers
- 130 people
- Sponsor
- Fidia Farmaceutici s.p.a.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.